Cargando…
Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies
The coronavirus disease 2019 (COVID-19) has been declared as pandemic by the World Health Organization and is causing substantial morbidity and mortality all over the world. Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COV...
Autores principales: | Longo, Miriam, Caruso, Paola, Maiorino, Maria Ida, Bellastella, Giuseppe, Giugliano, Dario, Esposito, Katherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375203/ https://www.ncbi.nlm.nih.gov/pubmed/32698837 http://dx.doi.org/10.1186/s12933-020-01090-9 |
Ejemplares similares
-
The residual cardiorenal risk in type 2 diabetes
por: Giugliano, Dario, et al.
Publicado: (2021) -
Mediterranean Diet and COVID-19: Hypothesizing Potential Benefits in People With Diabetes
por: Maiorino, Maria Ida, et al.
Publicado: (2020) -
SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021) -
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021) -
Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
por: Giugliano, Dario, et al.
Publicado: (2020)